NEW YORK (GenomeWeb News) – Piper Jaffray on Thursday initiated coverage of diagnostics firm Quidel with an Overweight rating, noting the San Diego-based company's move into the molecular diagnostics space.

The investment bank has a $26 price target on Quidel's stock.

Historically, Quidel has depended on its flu and respiratory virus business, and in a research note analyst William Quirk estimated that in 2011 that business made up 48 percent of total revenues.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.